Association Between Statin Use and Endometrial Cancer Survival

Nevadunsky, Nicole S.; Arsdale, Anne Van; Strickler, Howard D.; Spoozak, Lori; Moadel, Alyson B.; Kaur, Gurpreet; Girda, Eugenia; Goldberg, Gary L.; Einstein, Mark H.

doi:10.1097/aog.0000000000000926

Cited by 43 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 11 non-randomized studies involving more than 6,920 patients with endocrine-related gynecologic cancers were included in the meta-analysis, with 10 cohort studies [29, 31–39] and 1 case-control study [30]. Two of the 11 studies were published only in abstract form [35, 39].…”

Section: Resultsmentioning

confidence: 99%

“…Of these, 8 studies were carried out in the United States [29, 31–36, 39], 2 in Israel [30, 38], and 1 in China [37]. The effects of statins on mortality and progression in endometrial cancer [29–33] and ovarian cancer [29, 31, 34–39] were evaluated in 5 and 8 studies, respectively. The Newcastle–Ottawa scale values ranged from 4 to 8 stars: 1 study was awarded 4 stars, 2 studies were award 6 stars, and 6 studies were award 7 or more stars.…”

Section: Resultsmentioning

confidence: 99%

“…Three studies investigated the association between statin use and disease-specific survival (DSS) in endocrine-related gynecologic cancers [29, 31, 36]. The pooled data showed that statin use was significantly associated with improved DSS (HR, 0.72; 95% CI, 0.58 to 0.90).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Xie

Huang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included. Pooled hazard ratios (HRs) for overall survival, disease-specific survival and progression-free survival were calculated using a fixed-effects model. A total of 11 studies involving more than 6,920 patients with endocrine-related gynecologic cancers were identified. In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). Statin users also had improved disease-specific survival (3 studies, HR, 0.72; 95% CI, 0.58 to 0.90, I2 = 35.1%) and progression-free survival (3 studies, HR, 0.68; 95% CI, 0.49 to 0.93, I2 = 33.6%) in endocrine-related gynecologic cancers. Our findings support that statin use has potential survival benefits for patients with endocrine-related gynecologic cancers. Further large-scale prospective studies are required to validate our findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Xie

Huang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…19 This correlation remained after stratifying by histologic subtype and adjusting for clinical factors in women with nonendometrioid endometrial cancers. In comparison to our study population, this cohort contained a larger number of patients and similar percentage of patients with type 2 endometrial cancer taking statins, but did not report other demographic details.…”

Section: Discussionmentioning

confidence: 92%

“…Only one other article has specifically analyzed outcomes in patients with high-grade endometrial cancer using statins. 19 Thus, we investigated the effect of statin use on survival outcomes and recurrence rates in a large cohort of patients with endometrial cancer specifically with high-risk histology.…”

mentioning

confidence: 99%

Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer

Feng

Miller

Tenney

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review

Al‐kuraishy,

Al‐Maiahy,

Al‐Gareeb

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundEndometrial adenocarcinoma (EAC) is a malignant tumor of the endometrium. EAC is the most common female malignancy following the menopause period. About 40% of patients with EAC are linked with obesity and interrelated with hypertension, diabetes mellitus, and high circulating estrogen levels. Proprotein convertase (PC) furin was involved in the progression of EAC.Recent findingsFurin is a protease enzyme belonging to the subtilisin PC family called PC subtilisin/kexin type 3 that converts precursor proteins to biologically active forms and products. Aberrant activation of furin promotes abnormal cell proliferation and the development of cancer. Furin promotes angiogenesis, malignant cell proliferation, and tissue invasion by malignant cells through its pro‐metastatic and oncogenic activities. Furin activity is correlated with the malignant proliferation of EAC. Higher expression of furin may increase the development of EAC through overexpression of pro‐renin receptors and disintegrin and metalloprotease 17 (ADAM17). As well, inflammatory signaling in EAC promotes the expression of furin with further propagation of malignant transformation.ConclusionFurin is associated with the development and progression of EAC through the induction of proliferation, invasion, and metastasis of malignant cells of EAC. Furin induces ontogenesis in EAC through activation expression of ADAM17, pro‐renin receptor, CD109, and TGF‐β. As well, EAC‐mediated inflammation promotes the expression of furin with further propagation of neoplastic growth and invasion.

show abstract

Association Between Statin Use and Endometrial Cancer Survival

Abstract: Statin and aspirin use was associated with improved survival from nonendometrioid endometrial cancer.

Cited by 43 publications

References 25 publications

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer

The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review

Contact Info

Product

Resources

About